tements, including risks
associated with the timing and success of clinical trials and the
commercialization of product candidates, potential problems that may arise
in the clinical testing and approval process and Rigel's need for
additional capital, as well as other risks detailed from time to time in
Rigel's SEC reports, including its Form 10-Q for the quarter ended
September 30, 2007. Rigel does not undertake any obligation to update
forward-looking statements.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: rrodriguez@rigel.com
Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.com
'/>"/>SOURCE Rigel Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer2.
Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study3.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients4.
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer5.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain6.
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer7.
DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9478.
Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results9.
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice10.
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results11.
Amicus Therapeutics Announces Second Quarter 2007 Financial Results